PerkinElmer
check quantity

RediFect Red-FLuc-Puromycin

Lentiviral particles for tranduction of mammalian cell lines with a red-shifted luciferase transgene, for use in in vivo and other applications.

For laboratory use only. This product is intended for animal research only and not for use in humans.

Part Number
List Price
Your Price
Quantity
CLS960002
1575.00 USD
 
more
Buy Now

Please enter valid quantity

Please log in to add favorites.

NULL OR EMPTY CART

Overview

RediFect™ Red-FLuc-Puromycin Lentiviral Particles are self-inactivating, recombination incompetent lentiviral particles carrying red-shifted Luciola Italica luciferase transgene under control of the stable UbC promoter. The luciferase transgene is fused to the puromycin resistance gene via T2A “self-cleaving” linker peptide for efficient co-expression with selection marker. The lentiviral particles are pseudotyped with G glycoprotein from Vesicular Stomatitis Virus (VSVG), allowing efficient transduction of a wide variety of mammalian cells including most cancer cell lines, primary, stem and non-dividing cells.

  • Each vial contains 1 x 107 units/ml of lentiviral particles resuspended in 200 ul
  • The packaged material provides sufficient number of lentiviral particles for transduction of at least one cell line

We recommend using this product to transduce human cell lines, or murine cell lines that will be used in Nude and SCID mouse models only. An immune response may occur in syngeneic mouse models.

Specifications

Optical Imaging Classification Bioluminescence Imaging
Product Brand Name RediFect
Shipping Condition Dry Ice
Unit Size 1 Vial
Resources, Events & More
  • All

Ebook

In Vivo Imaging Solutions eBook

Researchers trust our in vivo imaging solutions to give them reliable, calibrated data that reveals pathway characterization and therapeutic efficacies for a broad range of indications. Our reagents, instruments, and applications support have helped hundreds of research projects over the years. And our hard-earned expertise makes us a trusted provider of pre-clinical imaging solutions— with more than 9,000 peer reviewed articles as proof.

PDF 4 MB

Flyer

Technical Note

White Paper

The Role of In Vivo Imaging in Drug Discovery and Development

The primary goal of preclinical imaging is to improve the odds of clinical success and reduce drug discovery and development time and costs. Advances in non-invasive in vivo imaging techniques have raised the use of animal models in drug discovery and development to a new level by enabling quick and efficient drug screening and evaluation. Read this White Paper to learn how preclinical in vivo imaging helps to ensure that smart choices are made by providing Go/No-Go decisions and de-risking drug candidates early on, significantly reducing time to the clinic and lowering costs all while maximizing biological understanding.

PDF 748 KB